Literature DB >> 33637203

Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

Alfred K Cheung1, Tara I Chang2, William C Cushman3, Susan L Furth4, Fan Fan Hou5, Joachim H Ix6, Gregory A Knoll7, Paul Muntner8, Roberto Pecoits-Filho9, Mark J Sarnak10, Sheldon W Tobe11, Charles R V Tomson12, Lyubov Lytvyn13, Jonathan C Craig14, David J Tunnicliffe15, Martin Howell15, Marcello Tonelli16, Michael Cheung17, Amy Earley17, Johannes F E Mann18.   

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorous process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence. The strength of recommendations is based on the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. The scope includes topics covered in the original guideline, such as optimal blood pressure targets, lifestyle interventions, antihypertensive medications, and specific management in kidney transplant recipients and children. Some aspects of general and cardiovascular health, such as lipid and smoking management, are excluded. This guideline also introduces a chapter dedicated to proper blood pressure measurement since all large randomized trials targeting blood pressure with pivotal outcomes used standardized preparation and measurement protocols adhered to by patients and clinicians. Based on previous and new evidence, in particular the Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure target of less than 120 mm Hg using standardized office reading for most people with chronic kidney disease (CKD) not receiving dialysis, the exception being children and kidney transplant recipients. The goal of this guideline is to provide clinicians and patients a useful resource with actionable recommendations supplemented with practice points. The burden of the recommendations on patients and resources, public policy implications, and limitations of the evidence are taken into consideration. Lastly, knowledge gaps and recommendations for future research are provided.
Copyright © 2021 KDIGO. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KDIGO; albuminuria; ambulatory blood pressure monitoring; angiotensin II receptor blocker; angiotensin-converting enzyme inhibitor; antihypertensive agents; automated office blood pressure; blood pressure measurement; blood pressure targets; children; chronic kidney disease; creatinine; diabetes; dietary sodium; evidence-based; guideline; home blood pressure monitoring; hyperkalemia; kidney transplant recipient; lifestyle; mineralocorticoid receptor antagonist; office blood pressure; physical activity; potassium; proteinuria; renin-angiotensin system; standardized office blood pressure; systematic review; weight loss

Mesh:

Substances:

Year:  2021        PMID: 33637203     DOI: 10.1016/j.kint.2020.10.026

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  37 in total

1.  Current antihypertensive treatment and treatment-resistant hypertension in Japanese patients with chronic kidney disease.

Authors:  Akihiro Tsuchimoto; Shigeru Tanaka; Hiromasa Kitamura; Hiroto Hiyamuta; Kazuhiko Tsuruya; Takanari Kitazono; Toshiaki Nakano
Journal:  Clin Exp Nephrol       Date:  2022-08-04       Impact factor: 2.617

2.  Markers of Kidney Tubular Secretion and Risk of Adverse Events in SPRINT Participants with CKD.

Authors:  Alexander L Bullen; Simon B Ascher; Rebecca Scherzer; Pranav S Garimella; Ronit Katz; Stein I Hallan; Alfred K Cheung; Kalani L Raphael; Michelle M Estrella; Vasantha K Jotwani; Rakesh Malhotra; Jesse C Seegmiller; Michael G Shlipak; Joachim H Ix
Journal:  J Am Soc Nephrol       Date:  2022-08-16       Impact factor: 14.978

Review 3.  Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.

Authors:  Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2022-09-22       Impact factor: 2.877

Review 4.  Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Angela Yee-Moon Wang; Robert Kalyesubula; Elke Schaeffner; Rajiv Agarwal
Journal:  Nat Rev Nephrol       Date:  2022-09-14       Impact factor: 42.439

5.  Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD.

Authors:  Martin Gritter; Rosa D Wouda; Stanley M H Yeung; Michiel L A Wieërs; Frank Geurts; Maria A J de Ridder; Christian R B Ramakers; Liffert Vogt; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn
Journal:  J Am Soc Nephrol       Date:  2022-05-24       Impact factor: 14.978

6.  Blood Pressure Lowering May Decrease Cognitive Decline; But Are We Ready to Lower Blood Pressure in the Real World?

Authors:  Madhuri Ramakrishnan; Gary Gronseth; Aditi Gupta
Journal:  J Clin Cardiol       Date:  2021

Review 7.  Updates in hypertension: new trials, targets and ways of measuring blood pressure.

Authors:  Liann Abu Salman; Jordana B Cohen
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-04       Impact factor: 3.416

Review 8.  Detecting and Treating Lung Congestion with Kidney Failure.

Authors:  Carmine Zoccali; Francesca Mallamaci; Eugenio Picano
Journal:  Clin J Am Soc Nephrol       Date:  2022-02-09       Impact factor: 10.614

9.  An easy-to-operate web-based calculator for predicting the progression of chronic kidney disease.

Authors:  Qian Xu; Yunyun Wang; Yiqun Fang; Shanshan Feng; Cuiyun Chen; Yanxia Jiang
Journal:  J Transl Med       Date:  2021-07-03       Impact factor: 5.531

Review 10.  A critical review of chronic kidney disease as a risk factor for coronary artery disease.

Authors:  Mark Coyle; Gerard Flaherty; Catriona Jennings
Journal:  Int J Cardiol Heart Vasc       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.